BioMarin Pharmaceutical | BMRN - Selling And Administration Expenses

Stock Price
64.08
Daily Change
0.66 1.04%
Monthly
12.88%
Yearly
-6.11%
Q1 Forecast
62.09

BioMarin Pharmaceutical reported $223.42M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Bayer EUR 3.4B 140M Sep/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Gilead Sciences USD 1.78B 425M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Insmed USD 212.48M 26.11M Dec/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Moderna USD 308M 40M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.75B 455M Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
United Therapeutics USD 152M 60.5M Sep/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025